Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: Implications for the design of antifungal agents

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Protein Science

• Publication date

  1996-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/PRO.5560050408PMID 8845753PMCID PMC2143388
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Candida acid proteinases.

  2009cited by this paper
• Candida albicans

  2003cited by this paper
• Engineering the substrate specificity of rhizopuspepsin: The role of Asp 77 of fungal aspartic proteinases in facilitating the cleavage of oligopeptide substrates with lysine in P1

  1995cited by this paper
• pH-dependent denaturation of extracellular aspartic proteinases from Candida species.

  1995cited by this paper
• Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors

  1995cited by this paper
• Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis.

  1995cited by this paper
• Expression of virulence factors in Candida albicans

  1995cited by this paper
• The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors.

  1995cited by this paper
• Extracellular aspartic proteinases from Candida albicans, Candida tropicalis, and Candida parapsilosis yeasts differ substantially in their specificities.

  1994cited by this paper
• A structural comparison of 21 inhibitor complexes of the aspartic proteinase from Endothia parasitica

  1994cited by this paper
• Multiplicity of genes encoding secreted aspartic proteinases in Candida species

  1994cited by this paper
• X-ray analysis at 2.0 A resolution of mouse submaxillary renin complexed with a decapeptide inhibitor CH-66, based on the 4-16 fragment of rat angiotensinogen.

  1994cited by this paper
• A fourth secreted aspartyl proteinase gene (SAP4) and a CARE2 repetitive element are located upstream of the SAP1 gene in Candida albicans

  1994cited by this paper
• Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans

  1994cited by this paper
• AMoRe: an automated package for molecular replacement

  1994cited by this paper
• Stimuli that induce production of Candida albicans extracellular aspartyl proteinase.

  1993cited by this paper
• The genes encoding the secreted aspartyl proteinases of Candida albicans constitute a family with at least three members

  1993cited by this paper
• X-ray crystallographic analysis of aspartic proteinases and their inhibitor complexes.

  1993cited by this paper
• X-ray analyses of aspartic proteinases. V. Structure and refinement at 2.0 A resolution of the aspartic proteinase from Mucor pusillus.

  1993cited by this paper
• PROCHECK: a program to check the stereochemical quality of protein structures

  1993cited by this paper
• A second gene for a secreted aspartate proteinase in Candida albicans

  1992cited by this paper
• Application of a fluorogenic substrate in the assay of proteolytic activity and in the discovery of a potent inhibitor of Candida albicans aspartic proteinase.

  1992cited by this paper
• Domain flexibility in aspartic proteinases

  1992cited by this paper
• Structure of a pepsin/renin inhibitor complex reveals a novel crystal packing induced by minor chemical alterations in the inhibitor.

  1992cited by this paper
• Characterization of the Bar proteinase, an extracellular enzyme from the yeast Saccharomyces cerevisiae.

  1991cited by this paper
• Putative virulence factors of Candida albicans.

  1991cited by this paper
• X-ray analyses of aspartic proteinases. IV. Structure and refinement at 2.2 A resolution of bovine chymosin.

  1991cited by this paper
• The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor.

  1991cited by this paper
• Comparative modeling of proteins in the design of novel renin inhibitors.

  1991cited by this paper
• Improved methods for building protein models in electron density maps and the location of errors in these models.

  1991cited by this paper
• Sequence of the Candida albicans gene encoding the secretory aspartate proteinase.

  1991cited by this paper
• Candida albicans acid proteinase: characterization and role in candidiasis.

  1991cited by this paper
• The three‐dimensional structure of recombinant bovine chymosin at 2.3 Å resolution

  1990cited by this paper
• The structure and function of the aspartic proteinases.

  1990cited by this paper
• Molecular and crystal structures of monoclinic porcine pepsin refined at 1.8 A resolution.

  1990cited by this paper
• Modulation of experimental systemic murine candidosis by intravenous pepstatin.

  1990cited by this paper
• Comparative production and rapid purification of Candida acid proteinase from protein-supplemented cultures

  1990cited by this paper
• The molecular replacement method.

  1990cited by this paper
• [Effect of pepstatin A on Candida albicans infection in the mouse].

  1990cited by this paper
• Revised 2.3 Å structure of porcine pepsin: Evidence for a flexible subdomain

  1990cited by this paper
• Structure and Function of the Aspartic Proteinases

  1990cited by this paper
• Nucleotide sequence of the Candida albicans aspartyl proteinase gene.

  1989cited by this paper
• High‐resolution X‐ray diffraction study of the complex between endothiapepsin and an oligopeptide inhibitor: the analysis of the inhibitor binding and description of the rigid body shift in the enzyme.

  1989cited by this paper
• Synthesis and biological activity of some transition-state inhibitors of human renin.

  1988cited by this paper
• Candida proteinases and candidosis.

  1988cited by this paper
• CandidaProteinases and Candidosis

  1988cited by this paper
• Crystallographic R Factor Refinement by Molecular Dynamics

  1987cited by this paper
• Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond.

  1987cited by this paper
• The structure of a synthetic pepsin inhibitor complexed with endothiapepsin.

  1987cited by this paper
• Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes.

  1987cited by this paper
• X-ray diffraction studies on penicillopepsin and its complexes: the hydrolytic mechanism

  1985cited by this paper
• Diffraction methods for biological macromolecules. Interactive computer graphics: FRODO.

  1985cited by this paper
• Structural evidence for gene duplication in the evolution of the acid proteases

  1978cited by this paper
• The Protein Data Bank: a computer-based archival file for macromolecular structures.

  1977cited by this paper
• Penicillopepsin from Penicillium janthinellum crystal structure at 2.8 Å and sequence homology with porcine pepsin

  1977cited by this paper

• Repurposing eugenol and cinnamaldehyde as potent antimicrobial agents: A comprehensive in-vitro and in-silico study.

  2025cites this paper
• Integrative evaluation of mycosynthesized silver nanoparticles against multidrug-resistant pathogens using microbiological and in silico approaches

  2025cites this paper
• Triggered Antifungal Therapy via Candida‐Responsive Hydrogels

  2025influential citation
• Elucidating the Virulence Roles of Secreted Aspartyl Proteinase (Sap1972) in Non-albicans Meyerozyma guilliermondii through Construction of a Structure-guided Mutant.

  2025cites this paper
• Secreted Aspartic Proteinases: Key Factors in Candida Infections and Host-Pathogen Interactions

  2024cites this paper
• Fungal Enzyme‐Responsive Hydrogel Drug Delivery Platform for Triggered Antifungal Release

  2024cites this paper
• Synergistic activity of Satureja intermedia and Ducrosia anethifolia essential oils and their interaction against foodborne pathogens: A multi-ligand molecular docking simulation

  2024cites this paper
• Detection of Secreted Aspartic Proteases (SAP) enzyme in the clinical isolates of Candida by Modified Stab Method

  2024cites this paper
• Computational modelling of the antimicrobial peptides Cruzioseptin-4 extracted from the frog Cruziohyla calcarifer and Pictuseptin-1 extracted from the frog Boana picturata

  2024cites this paper
• Antimicrobial, antioxidant, α-amylase and α-glucosidase inhibitory activities of a chemically characterized essential oil from Lavandula angustifolia Mill.,: in vitro and in silico investigations

  2023cites this paper
• Antioxidant, Volatile Compounds; Antimicrobial, Anti-Inflammatory, and Dermatoprotective Properties of Cedrus atlantica (Endl.) Manetti Ex Carriere Essential Oil: In Vitro and In Silico Investigations

  2023cites this paper
• Synthesis, Structural and Computational Studies of a novel anionic synthon and its derivatives

  2022cites this paper
• Micelle-like Nanoassemblies of Short Peptides Create Antimicrobial Selectivity in a Conventional Antifungal Drug

  2022cites this paper
• Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy

  2021cites this paper
• Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy

  2021cites this paper
• Opportunistic yeast pathogen Candida spp.: Secreted and membrane-bound virulence factors.

  2021cites this paper
• Aspartic peptidase of Phialophora verrucosa as target of HIV peptidase inhibitors: blockage of its enzymatic activity and interference with fungal growth and macrophage interaction

  2020cites this paper
• Crystal, spectral characterization, molecular docking, Hirshfeld computational studies and 3D-energy framework analysis of a novel puckered compound (C14H15Cl O): 2-Chloro-3-phenyl-5,5-dimethylcyclohex-2-en-1-one

  2020cites this paper
• Synthesis and physic-chemical properties of a novel chromate compound with potential biological applications, bis(2-phenylethylammonium) chromate(VI)

  2019cites this paper
• Theoretical and experimental study by DFT, molecular docking calculations and cytotoxicity assay of 7,7-dimethylaporphine alkaloids type isolated from Guatteria friesiana (Annonaceae)

  2019cites this paper
• Phenotypic and genotypic evaluation of adherence and biofilm development in Candida albicans respiratory tract isolates from hospitalized patients

  2019cites this paper
• Proteases and protease inhibitors in infectious diseases

  2018cites this paper
• Extracellular proteinases of Candida species pathogenic yeasts.

  2018cites this paper
• Fungal biofilm inhibition by piperazine‐sulphonamide linked Schiff bases: Design, synthesis, and biological evaluation

  2018cites this paper
• Biochemical characterization of a Kunitz inhibitor from Inga edulis seeds with antifungal activity against Candida spp.

  2018cites this paper
• Novel non-peptidic small molecule inhibitors of secreted aspartic protease 2 (SAP2) for the treatment of resistant fungal infections.

  2018cites this paper
• Roles of Candida albicans aspartic proteases in host-pathogen interactions

  2017cites this paper
• Non-opioid analgesic drug flupirtine: Spectral analysis, DFT computations, in vitro bioactivity and molecular docking study

  2017cites this paper
• CORRELATION OF PHENOTYPIC AND GENOTYPIC ADHESION AND BIOFILM FORMATION FEATURES IN CANDIDA ALBICANS STRAINS ISOLATED FROM DIFFERENT CLINICAL SPECIMENS

  2017cites this paper
• Spectroscopic investigation, vibrational assignments, HOMO-LUMO, NBO, MEP analysis and molecular docking studies of oxoaporphine alkaloid liriodenine.

  2017cites this paper
• PROTEIN ENGINEERING APPROACHES TO IMPROVING DIAGNOSIS AND TREATMENT OF CANDIDA ALBICANS INFECTIONS

  2017cites this paper
• The potential roles of Pinto bean (Phaseolus vulgaris cv. Pinto) bioactive peptides in regulating physiological functions: Protease activating, lipase inhibiting and bile acid binding activities

  2017cites this paper
• Structure–activity studies of protease activating, lipase inhibiting, bile acid binding and cholesterol-lowering effects of pre-screened cumin seed bioactive peptides

  2016cites this paper
• Discovery of Peptide Drugs as Enzyme Inhibitors and Activators

  2015cites this paper
• Atomic resolution crystal structure of Sapp2p, a secreted aspartic protease from Candida parapsilosis.

  2015cites this paper
• Design of Inhibitors of Aspartic Acid Proteases

  2015cites this paper
• Molecular modeling of abc transporter system — permease proteins from Microcoleus chthonoplastes PCC 7420 for effective binding against secreted aspartyl proteinases in Candida albicans — A therapeutic intervention

  2014cites this paper
• Extensive Expansion of A1 Family Aspartic Proteinases in Fungi Revealed by Evolutionary Analyses of 107 Complete Eukaryotic Proteomes

  2014cites this paper
• Design, synthesis, inhibition studies, and molecular modeling of pepstatin analogues addressing different secreted aspartic proteinases of Candida albicans.

  2013cites this paper
• Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors

  2013cites this paper
• Complex Formation and Catalytic Activity

  2013cites this paper
• Antifungal properties of the anti-hypertensive drug: aliskiren.

  2013cites this paper
• ROLE OF ASPARTIC PROTEINASES IN CANDIDA ALBICANS VIRULENCE. PART I. SUBSTRATE SPECIFICITY OF ASPARTIC PROTEINASES AND CANDIDA ALBICANS PATHOGENESIS

  2012cites this paper
• Experimental and Computational Active Site Mapping as a Starting Point to Fragment‐Based Lead Discovery

  2012cites this paper
• Aspartic protease inhibitors: effective drugs against the human fungal pathogen Candida albicans.

  2012cites this paper
• Role of aspartic proteinases in Candida albicans virulence. Part II. Expression of SAP1-10 aspartic proteinase during Candida albicans infections in vivo

  2012cites this paper
• Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype.

  2012cites this paper
• Novel small molecules for the treatment of infections caused by Candida albicans: a patent review (2002 – 2010)

  2011cites this paper
• Structure-based drug design strategies for inhibition of aspartic proteinases.

  2011cites this paper
• Aspartic protease inhibitors as potential anti-Candida albicans drugs: impacts on fungal biology, virulence and pathogenesis.

  2011cites this paper
• Protease expression by microorganisms and its relevance to crucial physiological/pathological events.

  2011cites this paper
• HIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos Santos.

  2010cites this paper
• Secreted Candida Proteins: Pathogenicity and Host Immunity

  2010cites this paper
• HIV aspartyl protease inhibitors as promising compounds against Candida albicans

  2010cites this paper
• Aspartic Peptidase Inhibitors as Potential Bioactive Pharmacological Compounds Against Human Fungal Pathogens

  2010cites this paper
• The crystal structure of the secreted aspartic protease 1 from Candida parapsilosis in complex with pepstatin A.

  2009cites this paper
• Targeting virulence: a new paradigm for antifungals.

  2009cites this paper
• Oral candidiasis of HIV-infected children undergoing sequential HIV therapies.

  2009cites this paper
• Two aspartic proteinases secreted by the pathogenic yeast Candida parapsilosis differ in expression pattern and catalytic properties

  2009cites this paper
• Cis‐Configured Aziridines Are New Pseudo‐Irreversible Dual‐Mode Inhibitors of Candida albicans Secreted Aspartic Protease 2

  2008cites this paper
• X‐ray structures of Sap1 and Sap5: Structural comparison of the secreted aspartic proteinases from Candida albicans

  2008cites this paper
• Evidence That the Bacillus subtilis SpoIIGA Protein Is a Novel Type of Signal-transducing Aspartic Protease*

  2008cites this paper
• Secreted proteins of Candida albicans.

  2008cites this paper
• Production of hybrid phage displaying secreted aspartyl proteinase epitope of Candida albicans and its application for the diagnosis of disseminated candidiasis

  2007cites this paper
• The crystal structure of the secreted aspartic proteinase 3 from Candida albicans and its complex with pepstatin A

  2007cites this paper
• The influence of Zn(II) and Mn(II) on catalytic activity of C. albicans aspartic proteinases

  2007cites this paper
• Structural requirements for proinflammatory activity of porin P2 Loop 7 from Haemophilus influenzae.

  2006cites this paper
• Cloning and characterization of Sapp2p, the second aspartic proteinase isoenzyme from Candida parapsilosis.

  2006cites this paper
• Formal total synthesis of the potent renin inhibitor aliskiren: application of a SmI2-promoted acyl-like radical coupling.

  2006cites this paper
• Structure-based specificity mapping of secreted aspartic proteases of Candida parapsilosis, Candida albicans, and Candida tropicalis using peptidomimetic inhibitors and homology modeling

  2006influential citation
• Candida albicans proteinases

  2006cites this paper
• Epitope mapping Candida albicans proteinase (SAP 2).

  2006cites this paper
• Current state of three-dimensional characterisation of antifungal targets and its use for molecular modelling in drug design.

  2005cites this paper
• The precursor of secreted aspartic proteinase Sapp1p from Candida parapsilosis can be activated both autocatalytically and by a membrane-bound processing proteinase

  2005cites this paper
• Hydrolytic enzymes as virulence factors of Candida albicans

  2005cites this paper
• Interaction studies of secreted aspartic proteases (Saps) from Candida albicans : application for drug discovery.

  2005cites this paper
• Trypsin inhibition by ferrocene

  2005cites this paper
• FCANAL: Structure based protein function prediction method. Application to enzymes and binding proteins

  2005cites this paper
• Molekulare und immunelektronenmikroskopische Untersuchungen zur Expression von sekretorischen Aspartatproteinasen in einem ex vivo Modell der vaginalen Kandidose und in vivo

  2005influential citation
• Crystal structure of aspartic proteinase from Irpex lacteus in complex with inhibitor pepstatin.

  2004cites this paper
• Small hydroxyethylene-based peptidomimetics inhibiting both HIV-1 and C. albicans aspartic proteases.

  2003cites this paper
• Candida albicans Secreted Aspartyl Proteinases in Virulence and Pathogenesis

  2003influential citation
• and Bernhard Proteinases in Virulence and Pathogenesis Secreted Aspartyl Candida albicans

  2003influential citation
• Aspartic Peptidase Inhibitors: Implications in Drug Development

  2003cites this paper
• Application and limitations of X-ray crystallographic data in structure-based ligand and drug design.

  2003cites this paper
• Aspartic proteinases in disease: a structural perspective.

  2002cites this paper
• The secreted aspartic proteinases as a new target in the therapy of candidiasis.

  2002cites this paper
• Inhibition of Candida albicans secreted aspartic protease by a novel series of peptidomimetics, also active on the HIV-1 protease.

  2002cites this paper
• Structure and mechanism of the pepsin-like family of aspartic peptidases.

  2002cites this paper
• Insights into the selective inhibition of Candida albicans secreted aspartyl protease: a docking analysis study.

  2002cites this paper
• Inhibition of BACE, a promising approach to Alzheimer's disease therapy.

  2002cites this paper
• Candida proteases and their inhibition: prospects for antifungal therapy.

  2001cites this paper
• Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.

  2001cites this paper
• Enzymological Characterization of Secreted Proteinases from Candida parapsilosis and Candida lusitaniae

  2001cites this paper
• Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts.

  2001cites this paper
• Analysis of crystal structures of aspartic proteinases: On the role of amino acid residues adjacent to the catalytic site of pepsin‐like enzymes

  2001cites this paper
• In search of an enzyme: the beta-secretase of Alzheimer's disease is an aspartic proteinase.

  2000cites this paper
• In search of an enzyme: the β-secretase of Alzheimer's disease is an aspartic proteinase

  2000cites this paper
• Protease inhibitors: current status and future prospects.

  2000cites this paper
• Conformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processing.

  2000cites this paper